Clinical trial
Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC
NCT00238615 · Stanford University, Other · Terminated
Key facts
| NCT number | NCT00238615 |
|---|---|
| Title | Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC |
| Official title | A Phase II Trial of Concurrent Docetaxel (Taxotere) / Carboplatin / Radiotherapy Followed by Surgical Resection Followed by Consolidation Taxotere / Carboplatin in Stage III Non-Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Stanford University, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Carcinoma, Non-Small-Cell Lung |
| Intervention type | Drug, Procedure |
| Interventions | Docetaxel, Carboplatin, Radiation therapy, Surgical resection |
| Enrollment | 13 |
| Start date | Mar 1, 2003 |
| Primary completion | Sep 1, 2009 |
| Completion | Nov 1, 2014 |
| First posted | Oct 13, 2005 |
| Last update posted | May 12, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: